Dana-Farber Cancer Institute | Strategic Alliance Partners

June 01, 2023

Lakshimi Nayak, MD, discusses the diagnosis of patients with primary CNS lymphoma.

May 30, 2023

Several phase 3 studies conducted by researchers from Dana-Farber Cancer Institute show promising results for patients with rectal, brain, and kidney cancers.

May 30, 2023

Investigators at Dana-Farber Cancer Institute in Boston, Massachusetts, developed a clinical outreach program combining diagnostic and patient navigation services.

May 25, 2023

A telephone and web-based weight loss intervention was successful in helping patients with breast cancer who were overweight or obese lose weight—which can ultimately lead to improved outcomes.

May 22, 2023

For the 11th consecutive year, OncLive is honored to recognize oncology leaders whose innovations have contributed to immeasurable improvements in outcomes for countless patients.

May 22, 2023

People living with HIV remain at higher risk than people living without HIV for developing various cancers that can be treated with immune checkpoint inhibitors.

May 20, 2023

The addition of cabozantinib to nivolumab and ipilimumab led to improved progression-free survival vs nivolumab and ipilimumab alone in patients with treatment-naïve advanced renal cell carcinoma; however, the rate of grade 3/4 adverse effects with the triplet was 79%.

May 17, 2023

The combination of osimertinib and platinum-based chemotherapy led to a statistically significant and clinically meaningful improvement in progression-free survival compared with osimertinib alone in patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR mutations.

May 16, 2023

A targeted kinase inhibitor added to a two-drug immunotherapy combination slowed the progression of advanced kidney cancer in previously untreated patients, according to research led by an oncologist from Dana-Farber Cancer Institute.

May 09, 2023

A new study published today in the New England Journal of Medicine found that for young women with hormone receptor-positive breast cancer, pausing endocrine therapy to pursue a pregnancy did not raise the short-term risk that the disease will recur.

April 28, 2023

In the open-label phase 2 LITESPARK-003 study, led by Dana-Farber Cancer Institute’s Toni Choueiri, MD, researchers investigated for the first time the combination of cabozantinib, a VEGF TKI, plus belzutifan, a HIF-2α inhibitor.

April 27, 2023

Bradley A. McGregor, MD, discusses the clinical significance of the updated COSMIC-021 data, how these findings support the continued investigation of IO/TKI combinations in non–clear cell renal cell carcinoma, and other efforts underway to better care for patients with varying histological subtypes of the disease.

April 25, 2023

Ursula A. Matulonis highlights previous data from the phase 3 ENGOT-OV16/NOVA trial initial readout and subsequent preplanned overall survival analysis, discusses new findings from the final analysis, and emphasizes how these data clarify some of the study’s limitations and reinforce the importance of adhering to the adjusted FDA label for niraparib in recurrent ovarian cancer.

April 17, 2023

In a new study in the journal Nature Cancer, Dana-Farber Cancer Institute scientists shed new light on the mechanism that raises and lowers PSMA expression in prostate cancer cells.

April 14, 2023

Bradley McGregor, MD, discusses the next steps for investigating cabozantinib plus atezolizumab in patients with advanced renal cell carcinoma.

April 14, 2023

Investigators of an ongoing phase 1a/1b multicohort trial are studying whether addition of adaptive immune activators increases the benefit derived from anti–PD-1 antibodies in multiple tumor types.

April 13, 2023

Christopher Lathan, MD, MS, MPH, discusses socioeconomical and clinical findings from a clinical outreach program incorporating cancer diagnostic services and patient navigation for patients from traditionally underserved populations.

April 10, 2023

Presenters from the 2023 SGO Annual Meeting share their insights on the treatment of patients with gynecologic cancers.

April 05, 2023

Research from Dana-Farber Cancer Institute looks at what happens before the emergence of mutations that interrupt cellular differentiation in colorectal cancer and finds not only evidence of fetal reprogramming that can initiate cancer, but also a protein, Sox9, that fuels that reprogramming.

April 04, 2023

Adagrasib induced high overall response rates in patients with KRAS G12C–mutated non–small cell lung cancer who achieved at least 90% mutation allele frequency clearance.